Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focus...
Incyte Corporation is a Wilmington, Delaware-ba...
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical compan...
Spero Therapeutics, Inc. is a multi-asset, clin...
Ocugen is a clinical stage biopharmaceutical company focused on discovering, devel...
Ocugen is a clinical stage biopharmaceutical co...
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed ...
EyePoint Pharmaceuticals, Inc. is a specialty b...
Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and develop...
Aptinyx Inc. is a clinical-stage biopharmaceuti...
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing no...
Madrigal Pharmaceuticals is a clinical-stage bi...
DermTech is the global leader in molecular dermatology, bringing precision medicin...
DermTech is the global leader in molecular derm...
Join the National Investor Network and get the latest information with your interests in mind.